½ÃÀ庸°í¼­
»óǰÄÚµå
1604590

¼¼°èÀÇ ´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ® ½ÃÀå : Á¦Ç°º°, Àç·áº°, ÃÖÁ¾ »ç¿ëÀÚº° - ¿¹Ãø(2025-2030³â)

Aortic Stent Grafts Market by Product (Abdominal Aortic Stent Graft, Thoracic Aortic Stent Graft), Material (Nitinol, Polyester Fabric, Stainless Steel), End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 199 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ® ½ÃÀåÀº 2023³â¿¡ 10¾ï 1,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 10¾ï 6,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, CAGR 6.21%·Î ¼ºÀåÇÒ Àü¸ÁÀ̰í, 2030³â¿¡´Â 15¾ï 5,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ® ½ÃÀåÀº ´ëµ¿¸Æ·ù¸¦ Ä¡·áÇϱâ À§ÇÑ ½ºÅÙÆ® ±×¶óÇÁÆ®ÀÇ Á¦Á¶ ¹× ¿ëµµ¿¡ ÁßÁ¡À» µÐ ´õ Å« ½ÉÀåÇ÷°ü Àåºñ »ê¾÷ÀÇ Àü¹® ºÎ¹®ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¼±Áø ÀÇ·á±â±â´Â Àúħ½À Ç÷°ü³» µ¿¸Æ·ù ¼öº¹¼ú(EVAR)¿¡ ºÒ°¡°áÇϸç, ±âÁ¸ÀÇ °³º¹¼ö¼ú°ú ºñ±³ÇÏ¿© ȸº¹½Ã°£ÀÇ ´ÜÃàÀ̳ª ¸®½ºÅ©ÀÇ Àú°¨°ú °°Àº ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù. ±× Àû¿ë ¹üÀ§´Â, º´¿øÀ̳ª Àü¹® Ŭ¸®´Ð µîÀÇ Çコ ÄÉ¾î ½Ã¼³¿¡ °ÉÃÄ, ÁÖ·Î º¹ºÎ³ª ÈäºÎÀÇ ´ëµ¿¸Æ·ù ȯÀÚ¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ®ÀÇ Çʿ伺Àº ´ëµ¿¸Æ·ùÀÇ ¼¼°è À¯º´·ü Áõ°¡, Àα¸ °í·ÉÈ­, ¼ö±â °á°ú¸¦ Çâ»ó½ÃŰ´Â ±â¼úÀÇ Áøº¸¿¡ ÀÇÇØ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù. ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â ÇコÄɾî ÁöÃâ Áõ°¡, Áø´Ü ±â¼ú Çâ»ó, Àúħ½À¼ö ±â¼ú äÅà Áõ°¡ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ºÐ±âÇüÀ̳ª ¿ïŸ¸®Çü µðÀÚÀÎÀÇ Â÷¼¼´ë ½ºÅÙÆ® ±×¶óÇÁÆ®, Ä¿½ºÅ͸¶ÀÌ¡ °¡´ÉÇÑ ÄÄÆ÷³ÍÆ®, »ýüÀûÇÕ¼º Àç·á µîÀÇ ±â¼ú Çõ½ÅÀº ÀÌÇØ°ü°èÀÚ¿¡°Ô À¯¸®ÇÑ ±âȸ¸¦ °¡Á®¿É´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ¸¦ Ȱ¿ëÇϱâ À§ÇØ ±â¾÷Àº Á¦Ç°ÀÇ À¯È¿¼º°ú ÀûÀÀ¼ºÀ» ³ôÀÌ´Â ¿¬±¸°³¹ß ÀÌ´Ï¼ÅÆ¼ºêÀÇ È®´ë¿¡ ÁÖ·ÂÇØ¾ß ÇÕ´Ï´Ù. ±×·¯³ª ÀÌ ½ÃÀåÀº ½ºÅÙÆ® ±×¶óÇÁÆ® ¼ö¼ú¿¡ µû¸¥ °í¾×ÀÇ ºñ¿ë°ú Á¦Ç° ½ÂÀÎÀ» ´ÊÃâ °¡´É¼ºÀÌ ÀÖ´Â ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç µîÀÇ Á¦¾à¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. º¹ÀâÇÑ EVAR ¼ö±â¸¦ ¼öÇàÇϱâ À§ÇÑ ¼÷·ÃµÈ Àü¹®°¡ ºÎÁ·ÀÌ ÀÌ·¯ÇÑ °úÁ¦¸¦ ´õ¿í ¾ÇÈ­½ÃŰ°í ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¼ú Çõ½ÅÀ» À§ÇÑ ÃÖ¼±ÀÇ ºÐ¾ß´Â ´Ù¾çÇÑ ÇØºÎÇÐÀû ±¸Á¶¿ÍÀÇ ÀûÇÕ¼ºÀ» Çâ»ó½Ã۱â À§ÇÑ ½ºÅÙÆ® ±×¶óÇÁÆ® ¼³°èÀÇ °³·®°ú Àå±â°£ÀÇ °æ°ú °üÂûÀÇ Çʿ伺À» ÁÙÀ̱â À§ÇÑ »ýºÐÇØ¼º Àç·áÀÇ Å½±¸¿¡ ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ °æÀïÀº ±â¼úÀû Áøº¸¿¡ °ßÀεǰí ÀÖ¾î ´ë±â¾÷Àº ¿¬±¸ °³¹ßÀ̳ª Àü·«Àû Á¦ÈÞ¿¡ °í¾×ÀÇ ÅõÀÚ¸¦ ½Ç½ÃÇϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§Çؼ­´Â ±â¾÷Àº ±ÔÁ¦ Áؼö¸¦ ¿ì¼±½ÃÇÏ°í ±â¼ú ±³·ù¸¦ À§ÇÑ ÆÄÆ®³Ê½ÊÀ» À°¼ºÇϸç ÀÓ»ó ¿ä±¸¿¡ ºÎÇÕÇÑ ¼Ö·ç¼ÇÀ» Á¦°øÇØ¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023³â) 10¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø³â(2024³â) 10¾ï 6,000¸¸ ´Þ·¯
¿¹Ãø³â(2030³â) 15¾ï 5,000¸¸ ´Þ·¯
CAGR(%) 6.21%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ® ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ® ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû °áÁ¤ Á¤¹ÐÈ­, »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ëÀ̳ª ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¼¼°èÀÇ ¼ÒºñÀÚ¿¡¼­ ´ëµ¿¸Æ·ù À¯º´·üÀÇ »ó½Â
    • °³º¹ ¼ö¼úº¸´Ù Ç÷°ü ³» ¼öº¹¼ú¿¡ ´ëÇÑ ±âÈ£ Áõ°¡
    • Àúħ½À ¼ö¼ú¿¡ ´ëÇÑ ±Þ¼ÓÇÑ °æ»ç
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ½ºÅÙÆ® ±×¶óÇÁÆ®ÀÇ À§Ä¡ ¾î±ß³²À̳ª óġ ÈÄÀÇ ÇÕº´Áõ¿¡ °üÇÑ ¿ì·Á
  • ½ÃÀå ±âȸ
    • ´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ®ÀÇ µðÀÚÀÎ °³¼±À» À§ÇÑ ÀÓ»ó½ÃÇè ¹× FDA ½ÂÀÎÀÇ ±ÞÁõ
    • »õ·Î¿î ÀÇ·á µî±ÞÀÇ Ã·´Ü Àç·áÀÇ µµÀÔ
  • ½ÃÀåÀÇ °úÁ¦
    • ¼÷·ÃµÈ °æÇè dzºÎÇÑ ÁÖÁ¦ Àü¹®°¡ÀÇ ºÎÁ·

Porter's Five Forces : ´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ® ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲÀÇ °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ® ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ® ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ® ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ® ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ® ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ® ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : ´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ® ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ ±æÀ» ±×¸³´Ï´Ù.

´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ® ½ÃÀåÀÇ Àü·«Àû ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð ¹× ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ ¹× ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À² ¹× °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¼¼°è ¼ÒºñÀÚ¿¡¼­ ´ëµ¿¸Æ·ù ÀÌȯÀ²ÀÇ »ó½Â
      • °³º¹ ¼ö¼ú¿¡ ÀÇÇÑ ¼öº¹º¸´Ù Ç÷°ü³» ¼öº¹ÀÌ ¼±È£µÇ´Â °æÇâ »ó½Â
      • Àúħ½À ¼ö¼ú¿¡ ´ëÇÑ ±Þ¼ÓÇÑ °æÇâ
    • ¾ïÁ¦¿äÀÎ
      • ½ºÅÙÆ® ±×¶óÇÁÆ®ÀÇ À߸øµÈ »ðÀÔ ¹× ¼ö¼ú ÈÄ ÇÕº´Áõ¿¡ ´ëÇÑ ¿ì·Á
    • ±âȸ
      • ´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ® ¼³°è °³¼±¿¡ °üÇÑ ÀÓ»ó½ÃÇè°ú FDA ½ÂÀÎ ±ÞÁõ
      • »õ·Î¿î ÀÇ·á µî±ÞÀÇ Ã·´Ü Àç·áÀÇ µµÀÔ
    • °úÁ¦
      • ¼÷·ÃµÈ °æÇèÀÌ Ç³ºÎÇÑ Àü¹®°¡ÀÇ ºÎÁ·
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå ´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ® ½ÃÀå : Á¦Ç°º°

  • º¹ºÎ ´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ®
  • ÈäºÎ ´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ®

Á¦7Àå ´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ® ½ÃÀå : ¼ÒÀ纰

  • ´ÏƼ³î
  • Æú¸®¿¡½ºÅÍ ¿ø´Ü
  • ½ºÅ×Àη¹½º ½ºÆ¿

Á¦8Àå ´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ® ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • Çмú±â°ü ¹× ¿¬±¸±â°ü
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • º´¿ø ¹× Ŭ¸®´Ð

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ® ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ® ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ´ëµ¿¸Æ ½ºÅÙÆ® ±×¶óÇÁÆ® ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼® ¹× Á¦¾È

±â¾÷ ¸ñ·Ï

  • Becton, Dickinson and Company
  • Bentley InnoMed GmbH
  • Braile Biomedica
  • Cardinal Health, Inc.
  • Cook Medical Inc.
  • CORCYM, Inc.
  • Cordis
  • Cryolife Inc.
  • Edwards Lifesciences Corporation
  • Endologix LLC
  • Endospan Ltd.
  • InSitu Technologies Inc.
  • JOTEC GmbH
  • Kawasumi Laboratories, Inc.
  • LeMaitre Vascular, Inc.
  • Lifetech Scientific(Shenzhen) Co., Ltd.
  • Medtronic PLC
  • MicroPort Scientific Corporation
  • Terumo Corporation
  • WL Gore & Associates Inc.
AJY 24.12.13

The Aortic Stent Grafts Market was valued at USD 1.01 billion in 2023, expected to reach USD 1.06 billion in 2024, and is projected to grow at a CAGR of 6.21%, to USD 1.55 billion by 2030.

The aortic stent grafts market is a specialized segment within the larger cardiovascular devices industry, focusing on the manufacture and application of stent grafts for treating aortic aneurysms. These advanced medical devices are crucial for minimally invasive endovascular aneurysm repair (EVAR), offering benefits such as reduced recovery time and lower risk compared to traditional open surgery. The scope of their application spans across healthcare facilities such as hospitals and specialized clinics, catering primarily to patients with abdominal or thoracic aortic aneurysms. The necessity of aortic stent grafts is driven by the increasing prevalence of aortic aneurysms globally, aging populations, and advancements in technology that enhance procedural outcomes. Key growth factors influencing the market include rising healthcare expenditures, improved diagnostic techniques, and an increasing adoption of minimally invasive procedures. Innovations such as next-generation stent grafts with branched or fenestrated designs, customizable components, and biocompatible materials present lucrative opportunities for stakeholders. To capitalize on these opportunities, companies should focus on expanding their research and development initiatives to enhance product efficacy and adaptability. However, the market faces limitations, including high costs associated with stent graft procedures and stringent regulatory requirements that may delay product approvals. Compounded by the shortage of skilled professionals for conducting complex EVAR procedures, these challenges can impede market growth. The best areas for innovation lie in refining stent graft design to improve compatibility with diverse anatomical structures and exploring biodegradable materials to reduce the need for long-term follow-up interventions. The nature of the market is competitive, driven by technological advancements, with leading players investing heavily in R&D and strategic collaborations. To thrive in this market, companies should prioritize regulatory compliance, foster partnerships for technological exchange, and align with clinical needs to deliver tailored solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 1.01 billion
Estimated Year [2024] USD 1.06 billion
Forecast Year [2030] USD 1.55 billion
CAGR (%) 6.21%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Aortic Stent Grafts Market

The Aortic Stent Grafts Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in the prevalence of aortic aneurysms among consumers across the globe
    • Growing preference for endovascular repair over open surgical repair
    • Rapid inclination towards minimally invasive surgeries
  • Market Restraints
    • Concern regarding misplacement and post-procedural complications of stent grafts
  • Market Opportunities
    • Surge in the number of clinical trials and FDA approvals for improvement of aortic stent graft designs
    • Introduction of novel medical-grade advanced materials
  • Market Challenges
    • Lack of skilled and experienced subject matter experts

Porter's Five Forces: A Strategic Tool for Navigating the Aortic Stent Grafts Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Aortic Stent Grafts Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Aortic Stent Grafts Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Aortic Stent Grafts Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Aortic Stent Grafts Market

A detailed market share analysis in the Aortic Stent Grafts Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Aortic Stent Grafts Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Aortic Stent Grafts Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Aortic Stent Grafts Market

A strategic analysis of the Aortic Stent Grafts Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Aortic Stent Grafts Market, highlighting leading vendors and their innovative profiles. These include Becton, Dickinson and Company, Bentley InnoMed GmbH, Braile Biomedica, Cardinal Health, Inc., Cook Medical Inc., CORCYM, Inc., Cordis, Cryolife Inc., Edwards Lifesciences Corporation, Endologix LLC, Endospan Ltd., InSitu Technologies Inc., JOTEC GmbH, Kawasumi Laboratories, Inc., LeMaitre Vascular, Inc., Lifetech Scientific (Shenzhen) Co., Ltd., Medtronic PLC, MicroPort Scientific Corporation, Terumo Corporation, and W. L. Gore & Associates Inc..

Market Segmentation & Coverage

This research report categorizes the Aortic Stent Grafts Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Abdominal Aortic Stent Graft and Thoracic Aortic Stent Graft.
  • Based on Material, market is studied across Nitinol, Polyester Fabric, and Stainless Steel.
  • Based on End-User, market is studied across Academic & Research Institutions, Ambulatory Surgical Centers, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the prevalence of aortic aneurysms among consumers across the globe
      • 5.1.1.2. Growing preference for endovascular repair over open surgical repair
      • 5.1.1.3. Rapid inclination towards minimally invasive surgeries
    • 5.1.2. Restraints
      • 5.1.2.1. Concern regarding misplacement and post-procedural complications of stent grafts
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in the number of clinical trials and FDA approvals for improvement of aortic stent graft designs
      • 5.1.3.2. Introduction of novel medical-grade advanced materials
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of skilled and experienced subject matter experts
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Aortic Stent Grafts Market, by Product

  • 6.1. Introduction
  • 6.2. Abdominal Aortic Stent Graft
  • 6.3. Thoracic Aortic Stent Graft

7. Aortic Stent Grafts Market, by Material

  • 7.1. Introduction
  • 7.2. Nitinol
  • 7.3. Polyester Fabric
  • 7.4. Stainless Steel

8. Aortic Stent Grafts Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic & Research Institutions
  • 8.3. Ambulatory Surgical Centers
  • 8.4. Hospitals & Clinics

9. Americas Aortic Stent Grafts Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Aortic Stent Grafts Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Aortic Stent Grafts Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Becton, Dickinson and Company
  • 2. Bentley InnoMed GmbH
  • 3. Braile Biomedica
  • 4. Cardinal Health, Inc.
  • 5. Cook Medical Inc.
  • 6. CORCYM, Inc.
  • 7. Cordis
  • 8. Cryolife Inc.
  • 9. Edwards Lifesciences Corporation
  • 10. Endologix LLC
  • 11. Endospan Ltd.
  • 12. InSitu Technologies Inc.
  • 13. JOTEC GmbH
  • 14. Kawasumi Laboratories, Inc.
  • 15. LeMaitre Vascular, Inc.
  • 16. Lifetech Scientific (Shenzhen) Co., Ltd.
  • 17. Medtronic PLC
  • 18. MicroPort Scientific Corporation
  • 19. Terumo Corporation
  • 20. W. L. Gore & Associates Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦